Recursion Pharmaceuticals (RXRX) EBIAT: 2020-2025
Historic EBIAT for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$162.3 million.
- Recursion Pharmaceuticals' EBIAT fell 69.29% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 89.42%. This contributed to the annual value of -$463.7 million for FY2024, which is 41.33% down from last year.
- Per Recursion Pharmaceuticals' latest filing, its EBIAT stood at -$162.3 million for Q3 2025, which was up 5.61% from -$171.9 million recorded in Q2 2025.
- In the past 5 years, Recursion Pharmaceuticals' EBIAT ranged from a high of -$30.7 million in Q1 2021 and a low of -$202.5 million during Q1 2025.
- In the last 3 years, Recursion Pharmaceuticals' EBIAT had a median value of -$95.8 million in 2024 and averaged -$120.8 million.
- Its EBIAT has fluctuated over the past 5 years, first tumbled by 152.01% in 2021, then increased by 11.46% in 2022.
- Over the past 5 years, Recursion Pharmaceuticals' EBIAT (Quarterly) stood at -$64.9 million in 2021, then grew by 11.46% to -$57.5 million in 2022, then plummeted by 61.75% to -$93.0 million in 2023, then slumped by 92.38% to -$178.9 million in 2024, then plummeted by 69.29% to -$162.3 million in 2025.
- Its last three reported values are -$162.3 million in Q3 2025, -$171.9 million for Q2 2025, and -$202.5 million during Q1 2025.